speb/financial-data huggingface dataset:
SUNPHARMA.NS income_statement (annual, 2023-03-31) — Reconciled Depreciation: 25304300000.00
SUNPHARMA.NS income_statement (annual, 2023-03-31) — Rent And Landing Fees: 588700000.00
SUNPHARMA.NS income_statement (annual, 2023-03-31) — Rent Expense Supplemental: 588700000.00
SUNPHARMA.NS cash_flow (annual, 2023-03-31) — Repayment Of Debt: -28996300000.00
SUNPHARMA.NS cash_flow (annual, 2023-03-31) — Repurchase Of Capital Stock: 0.00
SUNPHARMA.NS balance_sheet (annual, 2023-03-31) — Restricted Cash: 128900000.00
SUNPHARMA.NS income_statement (annual, 2023-03-31) — Restructuring And Mergern Acquisition: 70200000.00
SUNPHARMA.NS balance_sheet (annual, 2023-03-31) — Retained Earnings: 436102500000.00
SUNPHARMA.NS cash_flow (annual, 2023-03-31) — Sale Of Business: 0.00
SUNPHARMA.NS cash_flow (annual, 2023-03-31) — Sale Of Investment: 210457100000.00
SUNPHARMA.NS cash_flow (annual, 2023-03-31) — Sale Of PPE: 210100000.00
SUNPHARMA.NS income_statement (annual, 2023-03-31) — Selling And Marketing Expense: 52262400000.00
SUNPHARMA.NS income_statement (annual, 2023-03-31) — Selling General And Administration: 80447000000.00
SUNPHARMA.NS balance_sheet (annual, 2023-03-31) — Share Issued: 2399334970.00
SUNPHARMA.NS income_statement (annual, 2023-03-31) — Special Income Charges: -1808300000.00
SUNPHARMA.NS balance_sheet (annual, 2023-03-31) — Stockholders Equity: 559953800000.00
SUNPHARMA.NS balance_sheet (annual, 2023-03-31) — Tangible Book Value: 383105100000.00
SUNPHARMA.NS income_statement (annual, 2023-03-31) — Tax Effect Of Unusual Items: -163465323.65
SUNPHARMA.NS income_statement (annual, 2023-03-31) — Tax Provision: 8475900000.00
SUNPHARMA.NS income_statement (annual, 2023-03-31) — Tax Rate For Calcs: 0.09
SUNPHARMA.NS cash_flow (annual, 2023-03-31) — Taxes Refund Paid: -15098400000.00
SUNPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Assets: 807435900000.00
SUNPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Capitalization: 559953800000.00
SUNPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Debt: 68858700000.00
SUNPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Equity Gross Minority Interest: 593154700000.00
SUNPHARMA.NS income_statement (annual, 2023-03-31) — Total Expenses: 340015100000.00
SUNPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Liabilities Net Minority Interest: 214281200000.00
SUNPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Non Current Assets: 408602500000.00
SUNPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Non Current Liabilities Net Minority Interest: 15211200000.00
SUNPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Tax Payable: 3087100000.00
SUNPHARMA.NS income_statement (annual, 2023-03-31) — Total Unusual Items: -1814500000.00
SUNPHARMA.NS income_statement (annual, 2023-03-31) — Total Unusual Items Excluding Goodwill: -1814500000.00
SUNPHARMA.NS balance_sheet (annual, 2023-03-31) — Work In Process: 24973800000.00
SUNPHARMA.NS balance_sheet (annual, 2023-03-31) — Working Capital: 199763400000.00
SUNPHARMA.NS income_statement (annual, 2023-03-31) — Write Off: 1644300000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — +Operating Expense: 252207600000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — +Total Revenue: 477584500000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Accounts Payable: 56533000000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Accounts Receivable: 112493700000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Accumulated Depreciation: -125760400000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 11881600000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Allowance For Doubtful Accounts Receivable: -4058100000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Amortization: 11812200000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Amortization Cash Flow: 11812200000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Assets Held For Sale Current: 418700000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Available For Sale Securities: 53932900000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Basic Average Shares: 2399334970.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Basic EPS: 39.90
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Beginning Cash Position: 46237300000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 68026600000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Capital Expenditure: -22018100000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Capital Lease Obligations: 4279800000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Capital Stock: 2399300000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 92856500000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Short Term Investments: 193286500000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Cash Dividends Paid: -28981700000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Cash Equivalents: 68430800000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Cash Financial: 24425700000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Inventory: 5988100000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Other Current Assets: -3839000000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Other Current Liabilities: 2409200000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Payable: 2497200000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Receivables: 3528900000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Working Capital: 10621300000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Changes In Cash: 47346200000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Common Stock: 2399300000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Common Stock Equity: 636667500000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Common Stock Payments: -773900000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Construction In Progress: 12965100000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Cost Of Revenue: 120696600000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Assets: 434749800000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Capital Lease Obligation: 1256900000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Debt: 28443600000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Debt And Capital Lease Obligation: 29700500000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Deferred Taxes Liabilities: 4117000000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Liabilities: 169844000000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Provisions: 46743700000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Depreciation: 13755700000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Depreciation And Amortization: 25567900000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Depreciation And Amortization In Income Statement: 25567900000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Depreciation Income Statement: 13755700000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Derivative Product Liabilities: 0.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Diluted Average Shares: 2399334970.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Diluted EPS: 39.90
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: 95763800000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Dividends Payable: 113500000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Dividends Received Cfi: 991400000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — EBIT: 113263600000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — EBITDA: 138831500000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Effect Of Exchange Rate Changes: -739900000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — End Cash Position: 92856500000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Financial Assets: 0.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 6714900000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Financing Cash Flow: -67101600000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Finished Goods: 45807700000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Free Cash Flow: 99331700000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Gain Loss On Investment Securities: -1954900000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Gain Loss On Sale Of Business: 0.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Gain Loss On Sale Of PPE: 1662300000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — General And Administrative Expense: 34371400000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Goodwill: 85689900000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Goodwill And Other Intangible Assets: 173019800000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Gross Accounts Receivable: 116551800000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Gross PPE: 240648700000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Gross Profit: 356887900000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Hedging Assets Current: 349500000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Impairment Of Capital Assets: 1562600000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Interest Expense: 2384700000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Interest Expense Non Operating: 2384700000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Interest Income: 10229100000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Interest Income Non Operating: 10229100000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Interest Paid Cff: -2190300000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Interest Received Cfi: 6132000000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Inventory: 98682900000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Invested Capital: 665124400000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Investing Cash Flow: -6902000000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Investmentin Financial Assets: 60647800000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Investmentsin Associatesat Cost: 4061300000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Investmentsin Joint Venturesat Cost: 364800000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Issuance Of Debt: 45726500000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Land And Improvements: 10466200000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Long Term Capital Lease Obligation: 3022900000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Long Term Debt: 13300000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Long Term Debt And Capital Lease Obligation: 3036200000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Long Term Debt Issuance: 45726500000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Long Term Debt Payments: -81055900000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Long Term Equity Investment: 4426100000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Long Term Provisions: 141700000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Machinery Furniture Equipment: 149190800000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Minority Interest: 34591900000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Minority Interests: -336500000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Net Business Purchase And Sale: -2299100000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Net Common Stock Issuance: -773900000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Net Foreign Currency Exchange Gain Loss: -2499200000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Net Income: 95763800000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Net Income Common Stockholders: 95763800000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Net Income Continuous Operations: 96100300000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Net Income From Continuing And Discontinued Operation: 95763800000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Net Income From Continuing Operation Net Minority Interest: 95763800000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Net Income From Continuing Operations: 110878900000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Net Income Including Noncontrolling Interests: 96100300000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Net Interest Income: 7844400000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Net Investment Purchase And Sale: 10190400000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Net Issuance Payments Of Debt: -33899300000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Net Long Term Debt Issuance: -35329400000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Net Non Operating Interest Income Expense: 7844400000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Net PPE: 114888300000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Net PPE Purchase And Sale: -21709700000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Net Short Term Debt Issuance: 1430100000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Net Tangible Assets: 463647700000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Revenue: 4887400000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Assets: 41036500000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Liabilities: 1718600000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 3997200000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Non Current Prepaid Assets: 26219700000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Normalized EBITDA: 142938000000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Normalized Income: 99336455000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Operating Cash Flow: 121349800000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Operating Income: 104680300000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Operating Revenue: 477584500000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Ordinary Shares Number: 2399334970.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Other Cash Adjustment Outside Changein Cash: 12900000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Current Assets: 646700000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Current Liabilities: 9579200000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Equity Interest: 634268200000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Intangible Assets: 87329900000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Other Non Cash Items: -8136500000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Non Current Assets: 4739300000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Non Current Liabilities: 112000000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Other Non Operating Income Expenses: 1064900000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Other Operating Expenses: 46824800000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Payable: 13695700000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Properties: 101923200000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Receivables: 801300000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Short Term Investments: 100430000000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Other Special Charges: 2726300000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Otherunder Preferred Stock Dividend: 0.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Payables: 70342200000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 6831900000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Prepaid Assets: 27918900000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Pretax Income: 110878900000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Properties: 0.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Provisionand Write Offof Assets: 905900000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Purchase Of Business: -2299100000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Purchase Of Investment: -305714600000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Purchase Of PPE: -22018100000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Raw Materials: 32777600000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Reconciled Cost Of Revenue: 120696600000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Reconciled Depreciation: 25567900000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Rent And Landing Fees: 734300000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Rent Expense Supplemental: 734300000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Repayment Of Debt: -81055900000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Repurchase Of Capital Stock: -773900000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Restricted Cash: 151600000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Restructuring And Mergern Acquisition: 739500000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Retained Earnings: 501545500000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Sale Of Business: 0.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Sale Of Investment: 315905000000.00
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Sale Of PPE: 308400000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Selling And Marketing Expense: 57802600000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Selling General And Administration: 92174000000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Share Issued: 2399334970.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Special Income Charges: -5028400000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Stockholders Equity: 636667500000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Tangible Book Value: 463647700000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Tax Effect Of Unusual Items: -533845000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Tax Provision: 14394500000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Tax Rate For Calcs: 0.13
SUNPHARMA.NS cash_flow (annual, 2024-03-31) — Taxes Refund Paid: -15694400000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Assets: 854996500000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Capitalization: 636680800000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Debt: 32736700000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Equity Gross Minority Interest: 671259400000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Total Expenses: 372904200000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Liabilities Net Minority Interest: 183737100000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Non Current Assets: 420246700000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Non Current Liabilities Net Minority Interest: 13893100000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Tax Payable: 4117000000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Total Unusual Items: -4106500000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Total Unusual Items Excluding Goodwill: -4106500000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Treasury Shares Number: 0.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Work In Process: 20097600000.00
SUNPHARMA.NS balance_sheet (annual, 2024-03-31) — Working Capital: 264905800000.00
SUNPHARMA.NS income_statement (annual, 2024-03-31) — Write Off: 0.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Accounts Receivable: 129419900000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Assets Held For Sale Current: 366000000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Available For Sale Securities: 63351900000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Capital Lease Obligations: 4908300000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Capital Stock: 2399300000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 80125400000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 207553700000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Common Stock: 2399300000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 691149000000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Construction In Progress: 11501200000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Assets: 461054500000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Capital Lease Obligation: 1239400000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Debt: 20797900000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Debt And Capital Lease Obligation: 22037300000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Liabilities: 172552200000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Provisions: 57143500000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Goodwill: 87711900000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Goodwill And Other Intangible Assets: 182196000000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Gross PPE: 112483300000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Inventory: 99356500000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Invested Capital: 711960200000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 63351900000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Investmentsin Associatesat Cost: 4416200000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Investmentsin Joint Venturesat Cost: 366200000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Capital Lease Obligation: 3668900000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt: 13300000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 3682200000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Equity Investment: 4782400000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Provisions: 4037700000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Minority Interest: 2647500000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Net PPE: 112483300000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: 508953000000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Assets: 41735500000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Liabilities: 1887600000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Non Current Prepaid Assets: 10870700000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 2399334970.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Current Assets: 23884400000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 7042100000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Equity Interest: 688749700000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Intangible Assets: 94484100000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 4677800000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Liabilities: 4597500000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Properties: 100982100000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Receivables: 474000000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Payables: 63234600000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Share Issued: 2399334970.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: 691149000000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: 508953000000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Assets: 881156600000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 691162300000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Debt: 25719500000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: 693796500000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 187360100000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Assets: 420102100000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 14807900000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Tax Payable: 5910100000.00
SUNPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Working Capital: 288502300000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — +Operating Expense: 71345900000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — +Total Revenue: 134369400000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Basic Average Shares: 2399487603.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Basic EPS: 12.10
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Cost Of Revenue: 27405400000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Depreciation And Amortization In Income Statement: 6305600000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Depreciation Income Statement: 6305600000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Diluted Average Shares: 2399487603.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Diluted EPS: 12.10
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Diluted NI Availto Com Stockholders: 29033800000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — EBIT: 35279100000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — EBITDA: 41584700000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Gross Profit: 106964000000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Interest Expense: 515100000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Interest Expense Non Operating: 515100000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Minority Interests: -96000000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Income: 29033800000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Income Common Stockholders: 29033800000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Income Continuous Operations: 29129800000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing And Discontinued Operation: 29033800000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: 29033800000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Income Including Noncontrolling Interests: 29129800000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Interest Income: -515100000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Non Operating Interest Income Expense: -515100000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Normalized EBITDA: 44746400000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Normalized Income: 31687230623.06
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Operating Income: 35618100000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Operating Revenue: 134369400000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Other Non Operating Income Expenses: 4656200000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Other Operating Expenses: 41902700000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Otherunder Preferred Stock Dividend: 0.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Pretax Income: 34764000000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Reconciled Cost Of Revenue: 27405400000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Reconciled Depreciation: 6305600000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Special Income Charges: -3161700000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Tax Effect Of Unusual Items: -508269376.94
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Tax Provision: 5588600000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Tax Rate For Calcs: 0.16
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Total Expenses: 98751300000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Total Unusual Items: -3161700000.00
SUNPHARMA.NS income_statement (quarterly, 2024-12-31) — Total Unusual Items Excluding Goodwill: -3161700000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — +Operating Expense: 272625400000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — +Operating Expense: 74173300000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — +Total Revenue: 520412500000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — +Total Revenue: 128155800000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Accounts Payable: 61843400000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 61843400000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Accounts Receivable: 130461100000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 130461100000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Accumulated Depreciation: -135747800000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -135747800000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Additional Paid In Capital: 11881600000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 11881600000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -3262000000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -3262000000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Amortization: 12303300000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Amortization Cash Flow: 12303300000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Assets Held For Sale Current: 304100000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Assets Held For Sale Current: 304100000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Available For Sale Securities: 39480900000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 39480900000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Basic Average Shares: 2399334970.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Basic Average Shares: 2388755556.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Basic EPS: 45.60
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Basic EPS: 9.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Beginning Cash Position: 92856500000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Buildings And Improvements: 70515200000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 70515200000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Capital Expenditure: -21285800000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Capital Lease Obligations: 4925600000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 4925600000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Capital Stock: 2399300000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Capital Stock: 2399300000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Cash And Cash Equivalents: 102687700000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 102687700000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 263176400000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 263176400000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Cash Dividends Paid: -36139700000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Cash Equivalents: 69718200000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Cash Equivalents: 69718200000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Cash Financial: 32969500000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Cash Financial: 32969500000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Inventory: -1839700000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Other Current Assets: -593200000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Other Current Liabilities: 1820300000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Payable: 5279700000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Receivables: -16020500000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Working Capital: -3235600000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Changes In Cash: 8601100000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Common Stock: 2399300000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Common Stock: 2399300000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Common Stock Equity: 722180200000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 722180200000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Common Stock Payments: -28998500000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Construction In Progress: 14508100000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 14508100000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Cost Of Revenue: 121975100000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 26371900000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Assets: 526244700000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Assets: 526244700000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Capital Lease Obligation: 1368200000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 1368200000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Debt: 18671100000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Debt: 18671100000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Debt And Capital Lease Obligation: 20039300000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 20039300000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Deferred Taxes Liabilities: 7331800000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Deferred Taxes Liabilities: 7331800000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Liabilities: 181942100000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 181942100000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Provisions: 54364900000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Provisions: 54364900000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Depreciation: 13450600000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Depreciation And Amortization: 25753900000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Depreciation And Amortization In Income Statement: 25753900000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 6637900000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Depreciation Income Statement: 13450600000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 6637900000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Diluted Average Shares: 2399334970.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 2388755556.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Diluted EPS: 45.60
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Diluted EPS: 9.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Diluted NI Availto Com Stockholders: 109290400000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 21498800000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Dividends Payable: 149100000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Dividends Payable: 149100000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Dividends Received Cfi: 660200000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — EBIT: 139834900000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — EBIT: 33034900000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — EBITDA: 165588800000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — EBITDA: 39672800000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Effect Of Exchange Rate Changes: 1230400000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — End Cash Position: 102687700000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 4254400000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 4254400000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Financing Cash Flow: -79058200000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Finished Goods: 45738600000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Finished Goods: 45738600000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Free Cash Flow: 119435100000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Gain Loss On Investment Securities: -6136300000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Gain Loss On Sale Of Business: 217500000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Gain Loss On Sale Of PPE: 17800000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — General And Administrative Expense: 37235900000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Goodwill: 89394200000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Goodwill: 89394200000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Goodwill And Other Intangible Assets: 179599600000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 179599600000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Gross Accounts Receivable: 133723100000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 133723100000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Gross PPE: 250615300000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Gross PPE: 250615300000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Gross Profit: 398437400000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Gross Profit: 101783900000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Hedging Assets Current: 652500000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Hedging Assets Current: 652500000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Impairment Of Capital Assets: 71300000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Interest Expense: 2313600000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Interest Expense: 491400000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Interest Expense Non Operating: 2313600000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 491400000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Interest Income: 12301300000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Interest Income Non Operating: 12301300000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Interest Paid Cff: -2238200000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Interest Received Cfi: 8037500000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Inventory: 102433300000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Inventory: 102433300000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Invested Capital: 740876500000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Invested Capital: 740876500000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Investing Cash Flow: -53061600000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Investmentin Financial Assets: 43735300000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 43735300000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Investmentsin Associatesat Cost: 4014400000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Investmentsin Associatesat Cost: 4014400000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Investmentsin Joint Venturesat Cost: 472900000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Investmentsin Joint Venturesat Cost: 472900000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Issuance Of Debt: 33617000000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Land And Improvements: 10172700000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Land And Improvements: 10172700000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Capital Lease Obligation: 3557400000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 3557400000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Debt: 25200000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 25200000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 3582600000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 3582600000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Long Term Debt Issuance: 33617000000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Long Term Debt Payments: -43438400000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Equity Investment: 4487300000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Equity Investment: 4487300000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Provisions: 115800000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 115800000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Machinery Furniture Equipment: 155419300000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 155419300000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Minority Interest: 2679300000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Minority Interest: 2679300000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Minority Interests: -357100000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Minority Interests: -40500000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Net Business Purchase And Sale: -2728300000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Net Common Stock Issuance: -28998500000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: -3366700000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Net Income: 109290400000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income: 21498800000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Net Income Common Stockholders: 109290400000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 21498800000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Net Income Continuous Operations: 109647500000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 21539300000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 109290400000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 21498800000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 109290400000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 21498800000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Net Income From Continuing Operations: 137521300000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Net Income Including Noncontrolling Interests: 109647500000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 21539300000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Net Interest Income: 9987700000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Interest Income: -491400000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Net Investment Purchase And Sale: -38641500000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Net Issuance Payments Of Debt: -10303400000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Net Long Term Debt Issuance: -9821400000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Net Non Operating Interest Income Expense: 9987700000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -491400000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Net PPE: 114867500000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Net PPE: 114867500000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Net PPE Purchase And Sale: -20675700000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Net Short Term Debt Issuance: -482000000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Net Tangible Assets: 542580600000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 542580600000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Revenue: 3767400000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Revenue: 3767400000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Assets: 44075500000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 44075500000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Liabilities: 1924400000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 1924400000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 4534600000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 4534600000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Non Current Prepaid Assets: 7968000000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Non Current Prepaid Assets: 7968000000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Normalized EBITDA: 167254900000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 43289600000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Normalized Income: 110620662629.13
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Normalized Income: 23900079134.70
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Operating Cash Flow: 140720900000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Operating Income: 125812000000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Operating Income: 27610600000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Operating Revenue: 520412500000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Operating Revenue: 128155800000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Ordinary Shares Number: 2399334970.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 2399334970.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Other Cash Adjustment Outside Changein Cash: -300000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Current Assets: 733500000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 733500000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Current Liabilities: 10354400000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 10354400000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Equity Interest: 719780900000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Equity Interest: 719780900000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Intangible Assets: 90205400000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 90205400000.00